Conjugated Estrogens in the Treatment of Postmenopausal Women with Hyperparathyroidism

Publisher Website
Google Scholar
Abstract
Fourteen postmenopausal women with mild hyperparathyroidism were given conjugated estrogens. Serum Ca levels became normal and urinary Ca excretion was reduced for up to 2 yr in 10 patients taking an average dose of 1.25 mg of estrogen daily. Hypercalcemia returned quickly when therapy was interrupted. Estrogen did not systematically alter serum immunoreactive parathyroid hormone or calcitriol levels or urinary excretion of cAMP. Significant reductions in urinary hydroxyproline and serum alkaline phosphatase activity during estrogen therapy indicate that the major effect of therapy was to decrease bone turnover. Iliac crest biopsy specimens taken before estrogen therapy showed normal trabecular bone volume and excressive osteoid seams. Follow-up biopsy specimens were taken from 6 patients after 1 yr on therapy. Bone volume remained stable, but hyperosteoidosis had improved in only 1 patient. Without understanding the long-term impact of untreated mild hyperparathyroidism on bone, the benefits of estrogen therapy on bone remain uncertain. Therapy with conjugated estrogens provides sustained control of serum and urine Ca in most women with hyperparathyroidism and is a reasonable alternative in patients who are not surgical candidates.